Penicillin at the late stage of leptospirosis: a randomized controlled trial

Detalhes bibliográficos
Autor(a) principal: Costa, Everaldo
Data de Publicação: 2003
Outros Autores: Lopes, Antonio Alberto da Silva, Sacramento, Edilson, Costa, Yara Aragão, Matos, Eliana Dias, Lopes, Marcelo Barreto, Bina, José Carlos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/2224
Resumo: p. 141-145,May/June.
id UFBA-2_7710ea83ee7bb6a37b58fa8cf93cb055
oai_identifier_str oai:repositorio.ufba.br:ri/2224
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Costa, EveraldoLopes, Antonio Alberto da SilvaSacramento, EdilsonCosta, Yara AragãoMatos, Eliana DiasLopes, Marcelo BarretoBina, José CarlosCosta, EveraldoLopes, Antonio Alberto da SilvaSacramento, EdilsonCosta, Yara AragãoMatos, Eliana DiasLopes, Marcelo BarretoBina, José Carlos2011-08-17T20:03:20Z2011-08-17T20:03:20Z20030036-4665http://www.repositorio.ufba.br/ri/handle/ri/2224v. 45, n. 3.p. 141-145,May/June.Existe evidência de que o início precoce do tratamento com penicilina reduz a letalidade da leptospirose e de que a quimioprofilaxia é eficaz em pessoas expostas às fontes de infecção. Os dados existentes, contudo, são inconsistentes quanto ao benefício de iniciar penicilina na fase tardia da leptospirose. O presente estudo foi desenvolvido para avaliar se a introdução de penicilina após mais de quatro dias de sintomas reduz a letalidade da leptospirose. Um total de 253 pacientes entre 15 e 76 anos de idade, com leptospirose avançada, i.e., mais de quatro dias de sintomas, admitidos em um hospital de doenças infecciosas localizado em Salvador, Brasil, foram selecionados para o estudo. Os pacientes foram randomizados para um dos seguintes grupos de tratamento: com penicilina intravenosa, 6 milhões de unidades/dia (um milhão de unidades cada quatro horas) por 7 dias (n = 125) e sem penicilina (n = 128). O evento principal foi morte durante o período de internamento. A letalidade foi aproximadamente duas vezes maior no grupo tratado com penicilina (12%; 15/125) do que no grupo de comparação (6,3%; 8/128). Esta diferença seguiu direção oposta a da hipótese do estudo, porém não alcançou significância estatística (p = 0,112). A duração do internamento foi similar entre os grupos de tratamento. De acordo com os resultados do presente ensaio clínico randomizado o uso de penicilina não é benéfico em paciente com leptospirose quando iniciado com pelo menos quatro dias após o início dos sintomas. Portanto, maior atenção deve ser dada à prevenção e ao inicio mais precoce do tratamento da leptospirose.Submitted by JURANDI DE SOUZA SILVA (jssufba@hotmail.com) on 2011-08-17T20:03:20Z No. of bitstreams: 1 10375.pdf: 84310 bytes, checksum: c77bab2bac11048edbfac10eb5321217 (MD5)Made available in DSpace on 2011-08-17T20:03:20Z (GMT). No. of bitstreams: 1 10375.pdf: 84310 bytes, checksum: c77bab2bac11048edbfac10eb5321217 (MD5) Previous issue date: 2003São PauloLeptospirosisCase-fatality ratePrognosisDeath ratePenicillinRandomized clinical trialWeil's DiseasePenicillin at the late stage of leptospirosis: a randomized controlled trialRevista do Instituto de Medicina Tropical de São Pauloinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleengreponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAinfo:eu-repo/semantics/openAccessORIGINAL10375.pdf10375.pdfapplication/pdf84310https://repositorio.ufba.br/bitstream/ri/2224/1/10375.pdfc77bab2bac11048edbfac10eb5321217MD51LICENSElicense.txtlicense.txttext/plain1906https://repositorio.ufba.br/bitstream/ri/2224/2/license.txt29d163f9ff0fb3d07dcede351c3148b0MD52TEXT10375.pdf.txt10375.pdf.txtExtracted texttext/plain26926https://repositorio.ufba.br/bitstream/ri/2224/3/10375.pdf.txt30834f1ab8dd47ecb64b8c2c2d84c913MD53ri/22242022-07-05 14:03:21.098oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:03:21Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Penicillin at the late stage of leptospirosis: a randomized controlled trial
dc.title.alternative.pt_BR.fl_str_mv Revista do Instituto de Medicina Tropical de São Paulo
title Penicillin at the late stage of leptospirosis: a randomized controlled trial
spellingShingle Penicillin at the late stage of leptospirosis: a randomized controlled trial
Costa, Everaldo
Leptospirosis
Case-fatality rate
Prognosis
Death rate
Penicillin
Randomized clinical trial
Weil's Disease
title_short Penicillin at the late stage of leptospirosis: a randomized controlled trial
title_full Penicillin at the late stage of leptospirosis: a randomized controlled trial
title_fullStr Penicillin at the late stage of leptospirosis: a randomized controlled trial
title_full_unstemmed Penicillin at the late stage of leptospirosis: a randomized controlled trial
title_sort Penicillin at the late stage of leptospirosis: a randomized controlled trial
author Costa, Everaldo
author_facet Costa, Everaldo
Lopes, Antonio Alberto da Silva
Sacramento, Edilson
Costa, Yara Aragão
Matos, Eliana Dias
Lopes, Marcelo Barreto
Bina, José Carlos
author_role author
author2 Lopes, Antonio Alberto da Silva
Sacramento, Edilson
Costa, Yara Aragão
Matos, Eliana Dias
Lopes, Marcelo Barreto
Bina, José Carlos
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Costa, Everaldo
Lopes, Antonio Alberto da Silva
Sacramento, Edilson
Costa, Yara Aragão
Matos, Eliana Dias
Lopes, Marcelo Barreto
Bina, José Carlos
Costa, Everaldo
Lopes, Antonio Alberto da Silva
Sacramento, Edilson
Costa, Yara Aragão
Matos, Eliana Dias
Lopes, Marcelo Barreto
Bina, José Carlos
dc.subject.por.fl_str_mv Leptospirosis
Case-fatality rate
Prognosis
Death rate
Penicillin
Randomized clinical trial
Weil's Disease
topic Leptospirosis
Case-fatality rate
Prognosis
Death rate
Penicillin
Randomized clinical trial
Weil's Disease
description p. 141-145,May/June.
publishDate 2003
dc.date.issued.fl_str_mv 2003
dc.date.accessioned.fl_str_mv 2011-08-17T20:03:20Z
dc.date.available.fl_str_mv 2011-08-17T20:03:20Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/2224
dc.identifier.issn.none.fl_str_mv 0036-4665
dc.identifier.number.pt_BR.fl_str_mv v. 45, n. 3.
identifier_str_mv 0036-4665
v. 45, n. 3.
url http://www.repositorio.ufba.br/ri/handle/ri/2224
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/2224/1/10375.pdf
https://repositorio.ufba.br/bitstream/ri/2224/2/license.txt
https://repositorio.ufba.br/bitstream/ri/2224/3/10375.pdf.txt
bitstream.checksum.fl_str_mv c77bab2bac11048edbfac10eb5321217
29d163f9ff0fb3d07dcede351c3148b0
30834f1ab8dd47ecb64b8c2c2d84c913
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1808459374906048512